Skip to content

Study · Animal study (in vivo) · mouse · 2020

10 results

Intraperitoneal Treatment of Kisspeptin Suppresses Appetite and Energy Expenditure and Alters Gastrointestinal Hormones in Mice.

Dong TS, Vu JP, Oh S, Sanford D, Pisegna JR, Germano P

Digestive diseases and sciences15 Nov 2019Cited by 26 (Europe PMC)

PMID31729619 (opens in a new tab)DOI10.1007/s10620-019-05950-7 (opens in a new tab)PepBankPUB-31729619
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In adult mice, intraperitoneal kisspeptin‑10 significantly reduced food intake compared with vehicle.

    In plain wordsIn mice, kisspeptin‑10 injected into the abdomen reduced food intake compared with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseFood intake
    Study

    mousen = 32

    C57BL/6 wild-type adult mice in metabolic cages
    Comparator
    Vehicle
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2 nmol in 200 µl saline (10 µM) · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Intraperitoneal treatment with kisspeptin-10 caused a significant reduction in food intake, meal frequency, meal size, and eating rate.
    1 context sentence
    Summary · context
    Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In adult mice, intraperitoneal kisspeptin‑10 significantly reduced meal frequency compared with vehicle.

    In plain wordsIn mice, kisspeptin‑10 injected into the abdomen made mice eat fewer meals than vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseMeal frequency
    Study

    mousen = 32

    C57BL/6 wild-type adult mice in metabolic cages
    Comparator
    Vehicle
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2 nmol in 200 µl saline (10 µM) · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Intraperitoneal treatment with kisspeptin-10 caused a significant reduction in food intake, meal frequency, meal size, and eating rate.
    1 context sentence
    Summary · context
    Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In adult mice, intraperitoneal kisspeptin‑10 significantly reduced meal size compared with vehicle.

    In plain wordsIn mice, kisspeptin‑10 injected into the abdomen made meals smaller than with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseMeal size
    Study

    mousen = 32

    C57BL/6 wild-type adult mice in metabolic cages
    Comparator
    Vehicle
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2 nmol in 200 µl saline (10 µM) · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Intraperitoneal treatment with kisspeptin-10 caused a significant reduction in food intake, meal frequency, meal size, and eating rate.
    1 context sentence
    Summary · context
    Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In adult mice, intraperitoneal kisspeptin‑10 significantly reduced eating rate compared with vehicle.

    In plain wordsIn mice, kisspeptin‑10 injected into the abdomen made mice eat more slowly than with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseEating rate
    Study

    mousen = 32

    C57BL/6 wild-type adult mice in metabolic cages
    Comparator
    Vehicle
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2 nmol in 200 µl saline (10 µM) · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Intraperitoneal treatment with kisspeptin-10 caused a significant reduction in food intake, meal frequency, meal size, and eating rate.
    1 context sentence
    Summary · context
    Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In adult mice, kisspeptin‑10 significantly decreased total energy expenditure in both the dark and light phases compared with vehicle.

    In plain wordsIn mice, kisspeptin‑10 lowered the energy the body burned during both day and night compared with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseTotal energy expenditure (TEE)
    Study

    mousen = 32

    C57BL/6 wild-type adult mice in metabolic cages
    Comparator
    Vehicle
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    2 nmol in 200 µl saline (10 µM) · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Kisspeptin-10 significantly decreased TEE during both the dark and light phase cycles, while also increasing the RQ during the dark-phase cycle.
    1 context sentence
    Summary · context
    Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In adult mice, kisspeptin‑10 increased the respiratory quotient during the dark phase compared with vehicle.

    In plain wordsIn mice, kisspeptin‑10 raised the respiratory quotient at night compared with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseRespiratory quotient (RQ) in dark phase
    Study

    mousen = 32

    C57BL/6 wild-type adult mice in metabolic cages
    Comparator
    Vehicle
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    2 nmol in 200 µl saline (10 µM) · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Kisspeptin-10 significantly decreased TEE during both the dark and light phase cycles, while also increasing the RQ during the dark-phase cycle.
    1 context sentence
    Summary · context
    Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In adult mice, kisspeptin‑10 significantly raised plasma insulin compared with vehicle.

    In plain wordsIn mice, kisspeptin‑10 raised blood insulin compared with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    IncreasePlasma insulin
    Study

    mousen = 32

    C57BL/6 wild-type adult mice in metabolic cages
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 nmol in 200 µl saline (10 µM) · intraperitonealAs given in this study (mouse).

    Measurements

    Plasma insulin
    343.8 pg/ml
    kisspeptin-10
    Plasma insulin
    106.4 pg/ml
    vehicle

    Source sentences

    Summary
    In addition, mice injected with kisspeptin-10 had significantly higher plasma levels of insulin (343.8 pg/ml vs. 106.4 pg/ml; p = 0.005), leptin (855.5 pg/ml vs. 173.1 pg/ml; p = 0.02), resistin (9411.1 pg/ml vs. 4116.5 pg/ml; p = 0.001), and HDL (147.6 mg/dl vs 97.1 mg/dl; p = 0.04).
    1 context sentence
    Summary · context
    Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In adult mice, kisspeptin‑10 significantly raised plasma leptin compared with vehicle.

    In plain wordsIn mice, kisspeptin‑10 raised blood leptin compared with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    IncreasePlasma leptin
    Study

    mousen = 32

    C57BL/6 wild-type adult mice in metabolic cages
    Comparator
    Vehicle
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2 nmol in 200 µl saline (10 µM) · intraperitonealAs given in this study (mouse).

    Measurements

    Plasma leptin
    855.5 pg/ml
    kisspeptin-10
    Plasma leptin
    173.1 pg/ml
    vehicle

    Source sentences

    Summary
    In addition, mice injected with kisspeptin-10 had significantly higher plasma levels of insulin (343.8 pg/ml vs. 106.4 pg/ml; p = 0.005), leptin (855.5 pg/ml vs. 173.1 pg/ml; p = 0.02), resistin (9411.1 pg/ml vs. 4116.5 pg/ml; p = 0.001), and HDL (147.6 mg/dl vs 97.1 mg/dl; p = 0.04).
    1 context sentence
    Summary · context
    Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In adult mice, kisspeptin‑10 significantly raised plasma resistin compared with vehicle.

    In plain wordsIn mice, kisspeptin‑10 raised blood resistin compared with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    IncreasePlasma resistin
    Study

    mousen = 32

    C57BL/6 wild-type adult mice in metabolic cages
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Metabolic and weight
    Studied dose
    2 nmol in 200 µl saline (10 µM) · intraperitonealAs given in this study (mouse).

    Measurements

    Plasma resistin
    9411.1 pg/ml
    kisspeptin-10
    Plasma resistin
    4116.5 pg/ml
    vehicle

    Source sentences

    Summary
    In addition, mice injected with kisspeptin-10 had significantly higher plasma levels of insulin (343.8 pg/ml vs. 106.4 pg/ml; p = 0.005), leptin (855.5 pg/ml vs. 173.1 pg/ml; p = 0.02), resistin (9411.1 pg/ml vs. 4116.5 pg/ml; p = 0.001), and HDL (147.6 mg/dl vs 97.1 mg/dl; p = 0.04).
    1 context sentence
    Summary · context
    Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In adult mice, kisspeptin‑10 significantly raised plasma HDL compared with vehicle.

    In plain wordsIn mice, kisspeptin‑10 raised blood HDL cholesterol compared with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    IncreasePlasma HDL
    Study

    mousen = 32

    C57BL/6 wild-type adult mice in metabolic cages
    Comparator
    Vehicle
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2 nmol in 200 µl saline (10 µM) · intraperitonealAs given in this study (mouse).

    Measurements

    Plasma HDL
    147.6 mg/dl
    kisspeptin-10
    Plasma HDL
    97.1 mg/dl
    vehicle

    Source sentences

    Summary
    In addition, mice injected with kisspeptin-10 had significantly higher plasma levels of insulin (343.8 pg/ml vs. 106.4 pg/ml; p = 0.005), leptin (855.5 pg/ml vs. 173.1 pg/ml; p = 0.02), resistin (9411.1 pg/ml vs. 4116.5 pg/ml; p = 0.001), and HDL (147.6 mg/dl vs 97.1 mg/dl; p = 0.04).
    1 context sentence
    Summary · context
    Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.